C12N 2740/11045
Special targeting system for viral vectors
C12N2740/11045 (Special targeting system for viral vectors) appears on 7 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 7
- Assignees
- 7
- Inventors
- 15
- Latest grant
- 2 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- RNA-based delivery systems with levels of control2 Apr 2024US 11,946,066 B2California Institute of Technology
- Lysosomal storage disease enzymes24 Jan 2023US 11,560,554 B2Alexion Pharmaceuticals, Inc.
- RNA-based delivery systems with levels of control27 Sep 2022US 11,453,893 B2California Institute of Technology
- Lysosomal storage disease enzymes8 Dec 2020US 10,858,638 B2Alexion Pharmaceuticals, Inc.
- Lysosomal storage disease enzymes10 Sep 2019US 10,407,671 B2Alexion Pharmaceuticals, Inc.
- Glycoproteins for pseudotyping retroviral vector particles25 Dec 2025US 2025/0388924 A1Medizinische Hochschule Hannover
- Rna-based delivery systems with levels of control22 Jun 2023US 2023/0193317 A1California Institute of Technology
- Lysosomal storage disease enzymes10 Jun 2021US 2021/0171922 A1Alexion Pharmaceuticals, Inc.
- Rna-based delivery systems with levels of control5 Mar 2020US 2020/0071723 A1California Institute of Technology
- Lysosomal storage disease enzymes27 Feb 2020US 2020/0063113 A1Alexion Pharmaceuticals, Inc.
Most cited
By later US patents
- Methods of targeting of viral entry11US 6,060,316 AChildren's Medical Center Corporation · 2000
- Lysosomal storage disease enzymes2US 10,407,671 B2Alexion Pharmaceuticals, Inc. · 2019
- RNA-based delivery systems with levels of control1US 11,453,893 B2California Institute of Technology · 2022
- Use of constitutive transport elements for host range control1US 6,492,166 B1The United States of America, as represented by the Secretary, Department of Health and Human Services · 2002